Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Breast Neoplasms 3Sarcoma 2Prostatic Neoplasms 2Neoplasms, Plasma Cell 2Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Mesothelioma, Malignant 2Melanoma 2Glioblastoma 2Central Nervous System Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Brain Neoplasms 2Uterine Cervical Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Somatostatinoma 1Solitary Fibrous Tumor, Pleural 1Primary Myelofibrosis 1Pheochromocytoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oligodendroglioma 1Neuroendocrine Tumors 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Metastatic Non-hematologic Malignancies 1Meningioma 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

Temozolomide 85Radiotherapy 51Bevacizumab 31Irinotecan 19Radiation 16Carmustine 15Magnetic Resonance Spectroscopy 14Erlotinib Hydrochloride 14O(6)-benzylguanine 11Chemotherapy, Adjuvant 11Carboplatin 9sargramostim 8Thalidomide 8Imatinib Mesylate 8Filgrastim 8Surgical Procedures, Operative 6Gene Expression Profiling 6Drug Therapy 6pembrolizumab 5aldesleukin 5Topotecan 5Radiotherapy, Intensity-Modulated 5Hydroxyurea 5Gefitinib 5Etoposide 5Sorafenib 4Immunohistochemistry 4Dasatinib 4Celecoxib 4Biopsy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Gliosarcoma × vatalanib × Clear all
NCT00387933 2015-10-14

Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma

Duke University

Phase 1 Completed
37 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡